Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 75, Issue 2, 2005, Pages 215-220

  Boiardi, A ^a,b   Eoli, M ^a   Salmaggi, A ^a   Lamperti, E ^a   Botturi, A ^a   Broggi, G ^a   Bissola, L ^b   Finocchiaro, G ^b   Silvani, A ^a  

^a Department of Neuro Oncology ^*  (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Loco regional chemotherapy; Mitoxantrone; Recurrent glioblastoma; Rickam reservoir; Temozolomide

Indexed keywords

CARMUSTINE; CISPLATIN; MITOXANTRONE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; LEUKOPENIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; SEIZURE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR BURDEN;

EID: 29244460014     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-3030-x     Document Type: Article

References (42)

1. Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma: results of a systematic review of 1415 patients. Anticancer Res 18: 1303-1312, 1998
2. Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1-17, 1998
3. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, McCarty CS, Mahavley MS Jr, Mealey J, Owens G, Ransohoff J, Robertson JT: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1327, 1980
4. Fine HA, Dear KBG, Loeffler YS, Black PML, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993
5. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforne at first relapse. Br J Cancer 83: 588-593, 2000
6. Osoba D, Brada M, Prados MD, Yung WK: Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncol 4: 221-228, 2000
7. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, MacDonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 149-150, 2001
8. McDonald DR: Temozolomide for recurrent high-grade glioma. Semin Oncol 4: 3-12, 2001
9. Sipos L, Vitanovics D, Afra D: Treatment of recidive malignant gliomas with temozolomide. Ann Oncol 12: 259-266, 2001
10. Gaya A, Rees J, Greenstein A, Stebbing J: The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28: 115-120, 2002
11. Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M: Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol 57: 247-251, 2002
12. Prados M: Temozolomide in combination with other cytotoxic agents. Semin Oncol 28: 24-33, 2001
13. Newlands ES, Foster T, Zaknoen S: Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 21: 248-251, 2003
14. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97: 1963-1968, 2003
15. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. Clin Oncol 20: 1383-1388, 2002
16. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003
17. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 4: 39-43, 2002
18. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999
19. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C -> A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715-1719, 2001
20. Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS: Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol 3: 246-250, 2001
21. Boiardi A, Silvani A, Pozzi AL, Fariselli L, Broggi G, Salmaggi G: Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. J Neuroncol 41: 151-157, 1999
22. Boiardi A, Eoli M, Salmaggi A, Zappacosta B, Fariselli L, Milanesi I, Broggi G, Silvani A: Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 54: 39-47, 2001
23. MacDonald DR, Cascino TL, Clifford S: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
24. Bissola L, Eoli M, Silvani A, Polio B, Bianchissi D, Manghi F, Boiardi A, Finocchiaro G: MGMT promoter hypermethylation is more frequent in secondary GBM and is independent from other prognostic factor. Proceedings of the American association for Cancer research 95. Annual meeting 2004. Orlando, FL
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
27. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9: 2940-2949, 2003
28. Ermani M, Brandes A, Pasetto LM, Basso U, Reni M, Turazzi S, Berlucchi S, Ruzzolino P, Pinna G, Scienza R. Monfardini S, First line chemotherapy with cisplatin plus fractionated temozolomide [bid] in recurrent glioblastoma (GBM). Annual Meeting ASCO abs 2076. Orlando, 2000
29. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 15: 1963-1968, 2003
30. Brem H, Piantadossi S, Burger P, Walker M, Seiler RW: Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995
31. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Usgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41: 44-49, 1997
32. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39: 383-389, 1997
33. Perego P, Boiardi A, Carenini N, De Cesare M, Dolfini E, Giardino R, Magnani I, Silvani A, Soranzo C: Characterisation of an established human maligant glioblastoma cell line and its response to conventional garugs. J Cancer Res Clin Oncol 120: 585-592, 1994
34. Jordan JP, Hand CM, Markowitz RS, Black P: Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay. J Neurooncol 14: 19-35, 1992
35. Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schachenmayr W, Schonmayr R: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables. J Neurooncol 13: 13-24, 1992
36. Senkal M, Tonn JC, Schonmayr R, Schachenmayr W, Eickhoff U, Kelnen M, Kollig E: Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32: 203-208, 1997
37. Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V: Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol 6: 75-83, 1986
38. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H: Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125: 481-486, 1999
39. Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA: Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 70: 1255-1261, 1986
40. Di Meco F, Li KW, Tyler BM, Wolf AS, Brem H, Olivi A: Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 5: 1173-1178, 2002
41. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt E: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 38: 746-753, 1996
42. Broggi G, Ferroli P, Franzini A, Silvani A, Salmaggi A, Eoli M, Boiardi A: Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 98: 935-936, 2003